Iván Sánchez Fernández1, Tobias Loddenkemper2. 1. Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, United States; Department of Child Neurology, Sant Joan de Déu, Universidad de Barcelona, Barcelona, Spain. 2. Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, United States. Electronic address: tobias.loddenkemper@childrens.harvard.edu.
Abstract
PURPOSE: To estimate the cost of admissions related to status epilepticus (SE) in the USA and to evaluate SE mortality. METHOD: Descriptive retrospective study using national estimates from the KID's Inpatient Database (KID) for children and from the National Inpatient Sample (NIS) for adults for the years 2007-2012, the largest collection of all-payer, encounter-level hospital care data in the United States. The individual observation in this study is hospital admission. RESULTS: From a population of 186,013,640 admissions, a total of 184,500 admissions were related to SE. The median (p25-p75) cost of admissions related to SE was $7690 ($3893-$17,247) in the KID 2010-2012, $6529 ($3,370-$14,854) in the KID 2007-2009, $13,874 ($6699-$29,176) in the NIS 2012, $13,313 ($6,483-$28,598) in the NIS 2011, $12,999 ($6,366-$27,505) in the NIS 2010, $11,833 ($5721-$24,657) in the NIS 2009, $11,479 ($5,611-$24,326) in the NIS 2008, and $10,759 ($5493-$22,928) in the NIS 2007. Costs were more than two times higher for super-refractory SE admissions than for refractory SE admissions. Costs stratified by age followed an "U"-shaped distribution with higher costs in admissions of young children and older adults. Mortality ranged from 2.5% to 3% in children and from 12.7% to 14.9% in adults. CONCLUSIONS: This study estimates the cost of admissions related to SE in the USA to be approximately $7000 in children and $13,000 in adults, and quantifies how costs markedly increase once SE becomes super-refractory.
PURPOSE: To estimate the cost of admissions related to status epilepticus (SE) in the USA and to evaluate SE mortality. METHOD: Descriptive retrospective study using national estimates from the KID's Inpatient Database (KID) for children and from the National Inpatient Sample (NIS) for adults for the years 2007-2012, the largest collection of all-payer, encounter-level hospital care data in the United States. The individual observation in this study is hospital admission. RESULTS: From a population of 186,013,640 admissions, a total of 184,500 admissions were related to SE. The median (p25-p75) cost of admissions related to SE was $7690 ($3893-$17,247) in the KID 2010-2012, $6529 ($3,370-$14,854) in the KID 2007-2009, $13,874 ($6699-$29,176) in the NIS 2012, $13,313 ($6,483-$28,598) in the NIS 2011, $12,999 ($6,366-$27,505) in the NIS 2010, $11,833 ($5721-$24,657) in the NIS 2009, $11,479 ($5,611-$24,326) in the NIS 2008, and $10,759 ($5493-$22,928) in the NIS 2007. Costs were more than two times higher for super-refractory SE admissions than for refractory SE admissions. Costs stratified by age followed an "U"-shaped distribution with higher costs in admissions of young children and older adults. Mortality ranged from 2.5% to 3% in children and from 12.7% to 14.9% in adults. CONCLUSIONS: This study estimates the cost of admissions related to SE in the USA to be approximately $7000 in children and $13,000 in adults, and quantifies how costs markedly increase once SE becomes super-refractory.
Authors: Michael C Jin; Jonathon J Parker; Michael Zhang; Zack A Medress; Casey H Halpern; Gordon Li; John K Ratliff; Gerald A Grant; Robert S Fisher; Stephen Skirboll Journal: J Neurosurg Date: 2021-05-14 Impact factor: 5.115
Authors: Iván Sánchez Fernández; Nicholas S Abend; Marta Amengual-Gual; Anne Anderson; Ravindra Arya; Cristina Barcia Aguilar; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; Justice Clark; Raquel Farias-Moeller; William D Gaillard; Marina Gaínza-Lein; Tracy Glauser; Joshua Goldstein; Howard P Goodkin; Réjean M Guerriero; Yi-Chen Lai; Tiffani McDonough; Mohamad A Mikati; Lindsey A Morgan; Edward Novotny; Eric Payne; Katrina Peariso; Juan Piantino; Adam Ostendorf; Tristan T Sands; Kumar Sannagowdara; Robert C Tasker; Dimtry Tchapyjnikov; Alexis A Topjian; Alejandra Vasquez; Mark S Wainwright; Angus Wilfong; Kowryn Williams; Tobias Loddenkemper Journal: Neurology Date: 2020-07-01 Impact factor: 9.910
Authors: Judith L Z Weisenberg; Robert T Fitzgerald; John N Constantino; Melodie R Winawer; Liu Lin Thio Journal: Neurology Date: 2020-09-11 Impact factor: 9.910
Authors: Marina Gaínza-Lein; Cristina Barcia Aguilar; Juan Piantino; Kevin E Chapman; Iván Sánchez Fernández; Marta Amengual-Gual; Anne Anderson; Brian Appavu; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Justice Clark; Raquel Farias-Moeller; William D Gaillard; Tracy A Glauser; Joshua L Goldstein; Howard P Goodkin; Linda Huh; Robert Kahoud; Kush Kapur; Yi-Chen Lai; Tiffani L McDonough; Mohamad A Mikati; Lindsey A Morgan; Anuranjita Nayak; Edward Novotny; Adam P Ostendorf; Eric T Payne; Katrina Peariso; Latania Reece; James Riviello; Kumar Sannagowdara; Tristan T Sands; Theodore Sheehan; Robert C Tasker; Dmitry Tchapyjnikov; Alejandra Vasquez; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Bo Zhang; Tobias Loddenkemper Journal: Epilepsia Date: 2021-07-12 Impact factor: 6.740